FutureChemLtd Valuation
Is A220100 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A220100 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A220100's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A220100's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A220100?
Other financial metrics that can be useful for relative valuation.
What is A220100's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₩525.91b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 33.9x |
Enterprise Value/EBITDA | -196.8x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A220100's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 5.1x | ||
A268600 Cellivery Therapeutics | 10.9x | n/a | ₩244.9b |
A038290 Macrogen | 1.3x | 15.6% | ₩173.8b |
A278650 HLB bioStepLtd | 3.6x | n/a | ₩177.2b |
A039860 NanoEntek | 4.6x | n/a | ₩128.4b |
A220100 FutureChemLtd | 35.3x | n/a | ₩525.9b |
Price-To-Sales vs Peers: A220100 is expensive based on its Price-To-Sales Ratio (35.3x) compared to the peer average (3.2x).
Price to Earnings Ratio vs Industry
How does A220100's PE Ratio compare vs other companies in the KR Life Sciences Industry?
Price-To-Sales vs Industry: A220100 is expensive based on its Price-To-Sales Ratio (35.3x) compared to the KR Life Sciences industry average (3.9x).
Price to Sales Ratio vs Fair Ratio
What is A220100's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 35.3x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate A220100's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.